Prostate cancer is the second leading cancer killer in men. Men in general and African American men in particular face crucial decisions regarding prostate cancer screening and perhaps treatment for this disease. Major health organizations agree that men should discuss prostate cancer screening with their physicians or other health care professionals. The purpose of the study was to examine sociodemographic and other correlates of physician-patient discussions regarding the advantages and disadvantages of the prostate-specific antigen (PSA) test among African American men aged 40 or older. A majority of African American men reported having discussed the advantages and disadvantages of prostate cancer screening and/or testing with their physicians before ordering it, and physician-patient discussions about the PSA test were associated with increased screening in African American men. Inasmuch as African American men have greater prostate cancer incidence and mortality over other groups, future attempts should be made to find meaningful correlates of PSA screening and test use to help reduce the burden of this disease.
Agho, A.O., & Lewis, M.A. (2001). Correlates of actual and perceived knowledge of prostate cancer among African Americans. Cancer Nursing, 24(3), 165-171.
2.
American Cancer Society. (2007). Cancer facts & figures-2007. Atlanta, GA: Author.
3.
American Urological Association. (2000). Prostate specific antigen (PSA) best practice policy. Oncology , 14(2), 267-286.
4.
Blocker, D., Romocki, L., Thomas, K., Jones, B., Jackson, E., Reid, L., et al. (2006). Knowledge, beliefs and barriers associated with prostate cancer prevention and screening behaviors among African-American men. Journal of the National Medical Association, 98(8), 1286-1295.
5.
Chan, E.C., Vernon, S.W., O'Donnell, F.T., Ahn, C., Greisinger, A., & Aga, D.W. (2003). Informed consent for cancer screening with prostate-specific antigen: How well are men getting the message?American Journal of Public Health, 93(5), 779-785.
6.
Chan, E.C.Y., Vernon, S.W., Ahn, C., & Greisinger, A. (2004). Do men know that they have had a prostate-specific antigen test? Accuracy of self-reports of testing at 2 sites. American Journal of Public Health, 94(8), 1336-1338.
7.
Cooper, C., Merritt T.L., Ross, L.E., John, L.V., & Jorgensen, C.M. (2004). To screen or not to screen, when clinical guidelines disagree: Primary care physicians' use of the PSA test. Preventive Medicine, 38(2), 182-191.
8.
Demark-Wahnefried, W., Strigo, T., Conaway, M., Brunetti, M., Rimer, B.K., & Robertson, N. (1995). Knowledge, beliefs, and prior screening behavior among Blacks and Whites reporting for prostate cancer screening. Adult Urology, 46(3), 346-351.
9.
Dunn, A.S., Shridharani, K.V., Lou, W., Bernstein, J., & Horowitz, C.H. (2001). Physician-patient discussions of controversial cancer screening tests. American Journal of Preventive Medicine, 20(2), 130-134.
10.
Finney Rutten, L.J., Meissner, H.I., Breen, N., Vernon, S.W., & Rimer, B.K. (2005). Factors associated with men's use of prostate-specific antigen screening: Evidence from Health Information National Trends Survey . Preventive Medicine, 40(4), 461-468.
11.
Fowler, F.J., Bin, L., Collins, M.M., Roberts, R.G., Oesterling, J.E., Wasson, J.H., et al. (1998). Prostate cancer screening and beliefs about treatment efficacy: A national survey of primary care physicians and urologists . American Journal of Medicine, 104, 526-532.
12.
Gordon, N.P., Hiatt, R.A., & Lampert, D.I. (1993). Concordance of self-reported data and medical record audit for six cancer screening procedures. Journal of the National Cancer Institute, 85(7), 566-570.
13.
McFall, S.L. (2006). US men discussing prostate-specific antigen tests with a physician. Annals of Family Medincine, 4(5), 433-436.
14.
National Cancer Institute. (2005). Cancer trends progress report-2005 update. Bethesda, MD: Author.
15.
National Center for Health Statistics. (2002 ). National Center for Health Statistics: Data file documentation, national health interview survey, 2000 (machine-readable data file and documentation) . Atlanta, GA: Author.
16.
National Guideline Clearinghouse. (2005). Guideline synthesis: Screening for prostate cancer in: National Guideline Clearinghouse. National Guideline Clearinghouse. Retrieved April 7, 2007, from http://www.guideline.gov
17.
Rimer, B.K., Briss, P.A., Zeller, P.K., Chan, E.C.Y., & Woolf, S.H. (2004). Informed decision making: What is its role in cancer screening? Cancer, 101(5), 1214-1228.
18.
Ross, L.E., Breen, N., Uhler, R.J., Potosky, A.L., & Blackman, D. (2004). Prostate-specific antigen (PSA) test use reported in the 2000 National Health Interview Survey. Preventive Medicine , 38(6), 732-744.
19.
Ross, L.E., Richardson, L.C., & Berkowitz, Z. (2006). The effect of physician-patient discussions on the likelihood of prostate-specific antigen testing. Journal of the National Medical Association, 98(11), 1823-1829.
20.
Shah, B.V., Barnwell, B.G., & Bieler, G.S. (2004). SUDAAN. Research Triangle Park, NC: Research Triangle Institute.
21.
Stat bite. (2003). Stat bite: Prostate cancer incidence and mortality among white and black men, 1975-2000 . Journal of the National Cancer Institute, 95, 1357.
22.
Stroud, L.A., Ross, L.E., & Rose, S.W. (2006). Formative evaluation of the prostate cancer screening practices of African-American physicians. Journal of the National Medical Association, 98(10), 1637-1643.
23.
Swan, J., Breen, N., Coates, R.J., Rimer, B.K., & Lee, N.C. (2002). Progress in cancer screening practices in the United States: Results from the 2000 National Health Interview Survey. Cancer, 97(6), 1528-1540.
24.
Tannor, B.B., & Ross, L.E. (2006). Physician-patient discussions about prostate-specific antigen test use among African-American men. Journal of the National Medical Association, 98(4), 532-538.
25.
U.S. Department of Health and Human Services. ( 2000). Healthy people 2010: Understanding and improving health . Washington, DC: Author.
26.
Volk, R.J., & Cass, A.R. (2002). The accuracy of primary care patients' self-reports of prostate-specific antigen testing. American Journal of Preventive Medicine, 22(1), 56-58.
